Sign inJoin waitlistJoin the waitlist

Katherine Janeway

Director of Clinical Genomics, Dana-Farber Cancer Institute · Mass General Brigham

Credentials: · · ·

History

Mass General Brigham
Present
Mass General Brigham
Present

Pediatric Hematology Oncology
Boston Children's Hospital
2011–2014
Pediatrics
Boston Children's Hospital
2008–2011
Harvard Medical School
2004–2008

Research

Osteosarcoma
Review · Nature Reviews Disease Primers · 2022 · 559 citations
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
European Journal of Cancer · 2019 · 537 citations
Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations
Proceedings of the National Academy of Sciences of the United States of America · 2011 · First of 22 authors · Corresponding · 499 citations

Steven DuBois
55 papers
Richard Gorlick
47 papers
Alanna Church
34 papers
Brian Crompton
30 papers
DR
Damon Reed
25 papers
Douglas Hawkins
25 papers
David Shulman
21 papers · 2 as a fellow
Holcombe Grier
18 papers
Robert Randall
18 papers
JB
Julia Bender
16 papers
Nita Seibel
15 papers
Stephen Lessnick
13 papers

Grants

Count Me In: Partnering with Patients to Define the Clinical and Genomic Landscape of Rare Aggressive Sarcomas in Children and Adults
National Cancer Institute · U2C
Contact PI · $16.6M · Broad Institute, Inc.
2020–2027

Clinical trials

Olaparib With Ceralasertib in Recurrent Osteosarcoma
Principal investigator · Active not recruiting · Phase 2
Dana-Farber Cancer Institute
2020–2026
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2017–2026
Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
Principal investigator · Completed · Phase 2
Children's Oncology Group
2015–2023
The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study
Principal investigator · Active not recruiting
Dana-Farber Cancer Institute
2015–2026